{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:04:23Z","timestamp":1793394263626,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Evidence suggests that MDMA-assisted psychotherapy (MDMA-AP) has therapeutic potential for treatment of psychiatric illness. We conducted the first comprehensive systematic review and meta-analysis of the side effects of MDMA-AP across indications. We also assessed the quality of side effects-reporting in published trials of MDMA-AP. PubMed, EMBASE, PsycINFO, MEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL) were systematically searched. Phase 2 and 3 MDMA-AP studies were included; Phase 1 studies, which assessed MDMA without psychotherapy, were not. Quality of side effects-reporting was assessed against the CONSORT Harms 2022 guidelines. We also compared numbers of adverse events reported in publications to those recorded in ClinicalTrial.gov registers. Thirteen studies were included, with eight contributing to the meta-analysis. In Phase 2 studies, MDMA-AP was associated with increased odds of any side effect during medication sessions (OR\u2009=\u20091.67, 95%CI (1.12, 2.49)) and in the 7 days following (OR\u2009=\u20091.59, 95%CI (1.12, 2.24)) relative to control conditions. In Phase 3 studies, MDMA-AP was associated with increased odds of any adverse event during the treatment period relative to placebo-assisted psychotherapy (OR\u2009=\u20093.51, 95%CI (2.76, 4.46)). The majority of RCTs were rated as having high risk of bias. Certainty of the evidence was rated as very low to moderate according to the GRADE framework. No included RCT had adequate adherence to the CONSORT Harms 2022 recommendations and reporting rates were also low. Compared to placebo, MDMA-AP was associated with increased odds of side effects, which were largely transient and mild or moderate in severity. However, identified limitations in existing evidence indicate that further investigation is needed to better characterize the safety profile of MDMA-AP and guide implementation.<\/jats:p>","DOI":"10.1038\/s41386-024-01865-8","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T10:01:35Z","timestamp":1713866495000},"page":"1208-1226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"49","author":[{"given":"Julia","family":"Colcott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre A.","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7708-6154","authenticated-orcid":false,"given":"Olivia","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Meikle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillinder","family":"Bedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"key":"1865_CR1","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/00048674221127186","volume":"57","author":"G Bedi","year":"2023","unstructured":"Bedi G, Cotton SM, Guerin AA, Jackson HJ. MDMA-assisted psychotherapy for post-traumatic stress disorder: the devil is in the detail. Aust NZ J Psychiatry. 2023;57:476\u201381.","journal-title":"Aust NZ J Psychiatry"},{"key":"1865_CR2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","volume":"14","author":"SD Muthukumaraswamy","year":"2021","unstructured":"Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021;14:1133\u201352.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1865_CR3","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27:1025\u201333.","journal-title":"Nat Med"},{"key":"1865_CR4","doi-asserted-by":"crossref","unstructured":"Mitchell JM, Ot\u2019alora GM, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29:2473\u201380.","DOI":"10.1038\/s41591-023-02565-4"},{"key":"1865_CR5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/0269881121991792","volume":"35","author":"B Sessa","year":"2021","unstructured":"Sessa B, Higbed L, O\u2019Brien S, Durant C, Sakal C, Titheradge D, et al. First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. J Psychopharmacol. 2021;35:375\u201383.","journal-title":"J Psychopharmacol"},{"key":"1865_CR6","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","volume":"235","author":"AL Danforth","year":"2018","unstructured":"Danforth AL, Grob CS, Struble C, Feduccia AA, Walker N, Jerome L, et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacol (Berl). 2018;235:3137\u201348.","journal-title":"Psychopharmacol (Berl)"},{"key":"1865_CR7","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75706-1","volume":"10","author":"PE Wolfson","year":"2020","unstructured":"Wolfson PE, Andries J, Feduccia AA, Jerome L, Wang JB, Williams E, et al. MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. Sci Rep. 2020;10:20442.","journal-title":"Sci Rep."},{"key":"1865_CR8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jpsychires.2021.05.019","volume":"139","author":"AN Siegel","year":"2021","unstructured":"Siegel AN, Meshkat S, Benitah K, Lipsitz O, Gill H, Lui LMW, et al. Registered clinical studies investigating psychedelic drugs for psychiatric disorders. J Psychiatr Res. 2021;139:71\u201381.","journal-title":"J Psychiatr Res"},{"key":"1865_CR9","unstructured":"Therapeutic Goods Administration. Notice of final decision to amend (or not amend) the current Poisons Standard - June 2022 ACMS #38 - Psilocybine and MDMA 2023 [Available from: https:\/\/www.tga.gov.au\/resources\/publication\/scheduling-decisions-final\/notice-final-decision-amend-or-not-amend-current-poisons-standard-june-2022-acms-38-psilocybine-and-mdma"},{"key":"1865_CR10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/d41586-023-01296-3","volume":"616","author":"S Reardon","year":"2023","unstructured":"Reardon S. US could soon approve MDMA therapy \u2014 opening an era of psychedelic medicine. Nature. 2023;616:428\u201330.","journal-title":"Nature"},{"key":"1865_CR11","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/0269881117691569","volume":"31","author":"P Vizeli","year":"2017","unstructured":"Vizeli P, Liechti ME. Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol. 2017;31:576\u201388.","journal-title":"J Psychopharmacol"},{"key":"1865_CR12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamapsychiatry.2023.0099","volume":"80","author":"S McNamee","year":"2023","unstructured":"McNamee S, Devenot N, Buisson M. Studying harms is key to improving psychedelic-assisted therapy\u2014participants call for changes to research landscape. JAMA Psychiatry. 2023;80:411\u20132.","journal-title":"JAMA Psychiatry"},{"key":"1865_CR13","doi-asserted-by":"crossref","unstructured":"Meikle S, Carter O, Bedi G. Psychedelic-assisted psychotherapy, patient vulnerability and abuses of power. Aust NZ J Psychiatry. 2023:00048674231200164.","DOI":"10.31234\/osf.io\/gs7hd"},{"key":"1865_CR14","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1177\/02698811221116926","volume":"36","author":"JJ Breeksema","year":"2022","unstructured":"Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. J Psychopharmacol. 2022;36:1100\u201317.","journal-title":"J Psychopharmacol"},{"key":"1865_CR15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1177\/0269881116642542","volume":"30","author":"T Amoroso","year":"2016","unstructured":"Amoroso T, Workman M. Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy. J Psychopharmacol. 2016;30:595\u2013600.","journal-title":"J Psychopharmacol"},{"key":"1865_CR16","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2019.109735","volume":"96","author":"A Bahji","year":"2020","unstructured":"Bahji A, Forsyth A, Groll D, Hawken ER. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis. Prog Neuro-Psychopharmacol Biol Psychiatry. 2020;96:109735.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"1865_CR17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/02791072.2020.1769878","volume":"52","author":"JB Luoma","year":"2020","unstructured":"Luoma JB, Chwyl C, Bathje GJ, Davis AK, Lancelotta R. A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. J Psychoact Drugs. 2020;52:289\u201399.","journal-title":"J Psychoact Drugs"},{"key":"1865_CR18","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3390\/life11080765","volume":"11","author":"D Psiuk","year":"2021","unstructured":"Psiuk D, Nowak E, Cholewa K, \u0141opusza\u0144ska U, Samardakiewicz M. The potential role of serotonergic hallucinogens in depression treatment. Life. 2021;11:765.","journal-title":"Life"},{"key":"1865_CR19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00213-021-06027-y","volume":"239","author":"N Schimmers","year":"2022","unstructured":"Schimmers N, Breeksema JJ, Smith-Apeldoorn SY, Veraart J, van den Brink W, Schoevers RA. Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review. Psychopharmacology. 2022;239:15\u201333.","journal-title":"Psychopharmacology"},{"key":"1865_CR20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jcph.1995","volume":"62","author":"KW Smith","year":"2022","unstructured":"Smith KW, Sicignano DJ, Hernandez AV, White CM. MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: a systematic review with meta-analysis. J Clin Pharmacol. 2022;62:463\u201371.","journal-title":"J Clin Pharmacol"},{"key":"1865_CR21","volume":"13","author":"S Tedesco","year":"2021","unstructured":"Tedesco S, Gajaram G, Chida S, Ahmad A, Pentak M, Kelada M, et al. The efficacy of MDMA (3,4-Methylenedioxymethamphetamine) for post-traumatic stress disorder in humans: a systematic review and meta-analysis. Cureus. 2021;13:e15070.","journal-title":"Cureus"},{"key":"1865_CR22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/02791072.2020.1817639","volume":"53","author":"T Varker","year":"2021","unstructured":"Varker T, Watson L, Gibson K, Forbes D, O\u2019Donnell ML. Efficacy of psychoactive drugs for the treatment of posttraumatic stress disorder: a systematic review of MDMA, ketamine, LSD and psilocybin. J Psychoact Drugs. 2021;53:85\u201395.","journal-title":"J Psychoact Drugs"},{"key":"1865_CR23","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0269881120965915","volume":"35","author":"BJ Illingworth","year":"2021","unstructured":"Illingworth BJ, Lewis DJ, Lambarth AT, Stocking K, Duffy JM, Jelen LA, et al. A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis. J Psychopharmacol. 2021;35:501\u201311.","journal-title":"J Psychopharmacol"},{"key":"1865_CR24","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/00048674221083868","volume":"57","author":"S Kisely","year":"2023","unstructured":"Kisely S, Connor M, Somogyi AA, Siskind D. A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders. Aust NZ J Psychiatry. 2023;57:362\u201378.","journal-title":"Aust NZ J Psychiatry"},{"key":"1865_CR25","doi-asserted-by":"crossref","first-page":"e073725","DOI":"10.1136\/bmj-2022-073725","volume":"381","author":"DR Junqueira","year":"2023","unstructured":"Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, et al. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials. BMJ. 2023;381:e073725.","journal-title":"BMJ"},{"key":"1865_CR26","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1865_CR27","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023): Cochrane; 2023"},{"key":"1865_CR28","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","volume":"236","author":"MC Mithoefer","year":"2019","unstructured":"Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology. 2019;236:2735\u201345.","journal-title":"Psychopharmacology"},{"key":"1865_CR29","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1017\/S0033291723001058","volume":"53","author":"T Taillefer de Laportali\u00e8re","year":"2023","unstructured":"Taillefer de Laportali\u00e8re T, Jullien A, Yrondi A, Cestac P, Montastruc F. Reporting of harms in clinical trials of esketamine in depression: a systematic review. Psychological Med. 2023;53:4305\u201315.","journal-title":"Psychological Med"},{"key":"1865_CR30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3390\/vaccines10020313","volume":"10","author":"CT Yuniar","year":"2022","unstructured":"Yuniar CT, Pratiwi B, Ihsan AF, Laksono BT, Risfayanti I, Fathadina A, et al. Adverse events reporting quality of randomized controlled trials of COVID-19 vaccine using the CONSORT criteria for reporting harms: a systematic review. Vaccines. 2022;10:313.","journal-title":"Vaccines"},{"key":"1865_CR31","first-page":"64981","volume":"81","author":"National Institutes of Health","year":"2016","unstructured":"National Institutes of Health. Clinical trials registration and results information submission. Final rule. Fed Regist. 2016;81:64981\u20135157.","journal-title":"Fed Regist"},{"key":"1865_CR32","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"1865_CR33","volume":"7","author":"YK Loke","year":"2007","unstructured":"Loke YK, Price D, Herxheimer A, the Cochrane Adverse Effects Methods G. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol. 2007;7:32.","journal-title":"BMC Med Res Methodol"},{"key":"1865_CR34","unstructured":"Sch\u00fcnemann H, Brozek J, Guyatt G, Oxman A GRADE handbook for grading quality of evidence and strength of recommendations: The GRADE Working Group, 2013; 2013 [updated October 2013. Available from: https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"key":"1865_CR35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1590\/1516-4446-2020-0980","volume":"43","author":"Jardim","year":"2021","unstructured":"Jardim, Jardim AV, Chaves DV, Steglich BR, Ot\u2019alora GM M, Mithoefer MC, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil. Braz J Psychiatry. 2021;43:181\u20135.","journal-title":"Braz J Psychiatry"},{"key":"1865_CR36","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0269881110378371","volume":"25","author":"MC Mithoefer","year":"2011","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of +\/-3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2011;25:439\u201352.","journal-title":"J Psychopharmacol"},{"key":"1865_CR37","doi-asserted-by":"crossref","DOI":"10.1080\/20008198.2020.1840123","volume":"11","author":"CM Monson","year":"2020","unstructured":"Monson CM, Wagner AC, Mithoefer AT, Liebman RE, Feduccia AA, Jerome L, et al. MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial. Eur J Psychotraumatol. 2020;11:1840123.","journal-title":"Eur J Psychotraumatol"},{"key":"1865_CR38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/0269881112464827","volume":"27","author":"P Oehen","year":"2013","unstructured":"Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (\u00b13,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol. 2013;27:40\u201352.","journal-title":"J Psychopharmacol"},{"key":"1865_CR39","doi-asserted-by":"crossref","unstructured":"Oehen P, Gasser P. Using a MDMA- and LSD-group therapy model in clinical practice in Switzerland and highlighting the treatment of trauma-related disorders. Front Psychiatry. 2022;13:863552.","DOI":"10.3389\/fpsyt.2022.863552"},{"key":"1865_CR40","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/0269881118806297","volume":"32","author":"M Ot\u2019alora","year":"2018","unstructured":"Ot\u2019alora M, Grigsby J, Poulter B, Van Derveer JW, Giron SG, Jerome L, et al. 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. J Psychopharmacol. 2018;32:1295\u2013307.","journal-title":"J Psychopharmacol"},{"key":"1865_CR41","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","volume":"5","author":"MC Mithoefer","year":"2018","unstructured":"Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018;5:486\u201397.","journal-title":"Lancet Psychiatry"},{"key":"1865_CR42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/02791072.2008.10400637","volume":"40","author":"JC Bouso","year":"2008","unstructured":"Bouso JC, Doblin R, Farr\u00e9 M, Alc\u00e1zar M\u00c1, G\u00f3mez-Jarabo G. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J Psychoact Drugs. 2008;40:225\u201336.","journal-title":"J Psychoact Drugs"},{"key":"1865_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","volume":"76","author":"O Lingj\u00e6rde","year":"1987","unstructured":"Lingj\u00e6rde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987;76:1\u2013100.","journal-title":"Acta Psychiatr Scand"},{"key":"1865_CR44","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s00213-020-05548-2","volume":"237","author":"L Jerome","year":"2020","unstructured":"Jerome L, Feduccia AA, Wang JB, Hamilton S, Yazar-Klosinski B, Emerson A, et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology. 2020;237:2485\u201397.","journal-title":"Psychopharmacology"},{"key":"1865_CR45","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2466\/pms.1977.44.2.367","volume":"44","author":"DMA Gronwall","year":"1977","unstructured":"Gronwall DMA. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills. 1977;44:367\u201373.","journal-title":"Percept Mot Skills"},{"key":"1865_CR46","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","volume":"20","author":"C Randolph","year":"1998","unstructured":"Randolph C, Tierney MC, Mohr E, Chase TN. The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20:310\u20139.","journal-title":"J Clin Exp Neuropsychol"},{"key":"1865_CR47","unstructured":"Mitrushina M, Boone KB, Razani J, D\u2019Elia LF. Handbook of normative data for neuropsychological assessment, 2nd ed. New York, NY, US: Oxford University Press; 2005. xxii, 1029-xxii, p"},{"key":"1865_CR48","first-page":"16","volume":"6","author":"EB Carlson","year":"1993","unstructured":"Carlson EB, Putnam FW. An update on the dissociative experiences scale. Dissociation: Prog Dissociative Disord 1993;6:16\u201327.","journal-title":"Dissociation: Prog Dissociative Disord"},{"key":"1865_CR49","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1080\/03610911003650383","volume":"39","author":"H Chen","year":"2010","unstructured":"Chen H, Cohen P, Chen S. How big is a big odds ratio? Interpreting the magnitudes of odds ratios in epidemiological studies. Commun Stat - Simul Comput. 2010;39:860\u20134.","journal-title":"Commun Stat - Simul Comput"},{"key":"1865_CR50","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1360-0443.2006.01423.x","volume":"101","author":"CA Baylen","year":"2006","unstructured":"Baylen CA, Rosenberg H. A review of the acute subjective effects of MDMA\/ecstasy. Addiction. 2006;101:933\u201347.","journal-title":"Addiction"},{"key":"1865_CR51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jclinepi.2015.10.007","volume":"71","author":"R Meister","year":"2016","unstructured":"Meister R, von Wolff A, Mohr H, Nestoriuc Y, H\u00e4rter M, H\u00f6lzel L, et al. Adverse event methods were heterogeneous and insufficiently reported in randomized trials on persistent depressive disorder. J Clin Epidemiol. 2016;71:97\u2013108.","journal-title":"J Clin Epidemiol"},{"key":"1865_CR52","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1176\/appi.ajp.161.9.1692","volume":"161","author":"PN Papanikolaou","year":"2004","unstructured":"Papanikolaou PN, Churchill R, Wahlbeck K, Ioannidis JPA, The EU-PSI Project. Safety reporting in randomized trials of mental health interventions. Am J Psychiatry. 2004;161:1692\u20137.","journal-title":"Am J Psychiatry"},{"key":"1865_CR53","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.arth.2022.06.004","volume":"37","author":"JM Anderson","year":"2022","unstructured":"Anderson JM, Howard C, Staggs J, Steele R, Strasser T, Small T, et al. Inadequate reporting of complications in randomized controlled trials cited as supporting evidence underpinning AAOS CPG recommendations for hip and knee osteoarthritis: application of the CONSORT harms checklist. J Arthroplast. 2022;37:2466\u201372 e2.","journal-title":"J Arthroplast"},{"key":"1865_CR54","doi-asserted-by":"crossref","DOI":"10.1186\/s40510-023-00457-4","volume":"24","author":"DT Alfailany","year":"2023","unstructured":"Alfailany DT, Hajeer MY, Darwich K. The transparency of reporting \u2018harms\u2019 encountered with the surgically assisted acceleration of orthodontic tooth movement in the published randomized controlled trials: a meta-epidemiological study. Prog Orthod. 2023;24:11.","journal-title":"Prog Orthod"},{"key":"1865_CR55","doi-asserted-by":"crossref","unstructured":"Allen EN, Chandler CIR, Mandimika N, Leisegang C, Barnes K. Eliciting adverse effects data from participants in clinical trials. Cochrane Database Syst Rev. 2018;1:MR000039.","DOI":"10.1002\/14651858.MR000039.pub2"},{"key":"1865_CR56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1176\/appi.ajp.2016.16020225","volume":"174","author":"BR Rutherford","year":"2017","unstructured":"Rutherford BR, Wall MM, Brown PJ, Choo TH, Wager TD, Peterson BS, et al. Patient expectancy as a mediator of placebo effects in antidepressant clinical trials. Am J Psychiatry. 2017;174:135\u201342.","journal-title":"Am J Psychiatry"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01865-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01865-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01865-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T10:08:38Z","timestamp":1720087718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01865-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1865"],"URL":"https:\/\/doi.org\/10.1038\/s41386-024-01865-8","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]},"assertion":[{"value":"1 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}